Pandit-Taskar N - Search Results

1

Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.

Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O'Donoghue JA, Nacca A, Smith-Jones P, Schwartz L, Slovin S, Finn R, Larson S, Scher HI. Morris MJ, et al. Clin Cancer Res. 2007 May 1;13(9):2707-13. doi: 10.1158/1078-0432.CCR-06-2935. Clin Cancer Res. 2007. PMID: 17473203 Clinical Trial.

2

Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease.

Prasad K, Serencsits BE, Chu BP, Dauer LT, Donzelli M, Basu E, Kramer K, Pandit-Taskar N. Prasad K, et al. Res Sq [Preprint]. 2024 Feb 28:rs.3.rs-3969388. doi: 10.21203/rs.3.rs-3969388/v1. Res Sq. 2024. Update in: EJNMMI Res. 2024 Jul 31;14(1):70. doi: 10.1186/s13550-024-01127-0 PMID: 38464207 Free PMC article. Updated. Preprint.

3

Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem.

Saboury B, Bradshaw T, Boellaard R, Buvat I, Dutta J, Hatt M, Jha AK, Li Q, Liu C, McMeekin H, Morris MA, Scott PJH, Siegel E, Sunderland JJ, Pandit-Taskar N, Wahl RL, Zuehlsdorff S, Rahmim A. Saboury B, et al. J Nucl Med. 2023 Feb;64(2):188-196. doi: 10.2967/jnumed.121.263703. Epub 2022 Dec 15. J Nucl Med. 2023. PMID: 36522184 Free PMC article.

4

New strategies in radioimmunotherapy for lymphoma.

Pandit-Taskar N, Hamlin PA, Reyes S, Larson SM, Divgi CR. Pandit-Taskar N, et al. Curr Oncol Rep. 2003 Sep;5(5):364-71. doi: 10.1007/s11912-003-0020-z. Curr Oncol Rep. 2003. PMID: 12895386

5

Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Morris MJ, et al. Curr Oncol Rep. 2004 May;6(3):222-9. doi: 10.1007/s11912-004-0053-y. Curr Oncol Rep. 2004. PMID: 15066234 Review.

6

Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.

Pandit-Taskar N, Batraki M, Divgi CR. Pandit-Taskar N, et al. J Nucl Med. 2004 Aug;45(8):1358-65. J Nucl Med. 2004. PMID: 15299062 Free article. Review.

7

Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET.

Pandit-Taskar N, Schöder H, Gonen M, Larson SM, Yeung HW. Pandit-Taskar N, et al. AJR Am J Roentgenol. 2004 Oct;183(4):1143-7. doi: 10.2214/ajr.183.4.1831143. AJR Am J Roentgenol. 2004. PMID: 15385321

8

PET: too much of a good thing? Does the plethora of choices impact on patient management?

Divgi C, Pandit-Taskar N. Divgi C, et al. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):398. doi: 10.1007/s00259-005-1777-0. Eur J Nucl Med Mol Imaging. 2005. PMID: 15761778 No abstract available.

9

Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Morris MJ, et al. Curr Urol Rep. 2005 May;6(3):163-70. doi: 10.1007/s11934-005-0003-8. Curr Urol Rep. 2005. PMID: 15869719 Review.

10

JNM supplement on molecular radiotherapy.

Wong CO, Pandit-Taskar N, Larson SM. Wong CO, et al. J Nucl Med. 2005 Oct;46(10):1765-6; author reply 1766. J Nucl Med. 2005. PMID: 16204728 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters